118 related articles for article (PubMed ID: 17300231)
1. Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma.
Fearfield LA; Larkin JM; Rowe A; A'Hern R; Fisher C; Francis N; MacKie R; McCann B; Gore ME; Bunker CB
Br J Dermatol; 2007 Mar; 156(3):440-7. PubMed ID: 17300231
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
3. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
4. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
5. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
6. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
7. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
8. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions.
Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J
Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642
[TBL] [Abstract][Full Text] [Related]
9. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy.
Pearl RA; Pacifico MD; Richman PI; Wilson GD; Grover R
J Plast Reconstr Aesthet Surg; 2008; 61(3):265-71. PubMed ID: 17569608
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
11. FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study.
Bozdogan N; Bozdogan O; Pak I; Atasoy P
Int J Dermatol; 2010 Jul; 49(7):761-7. PubMed ID: 20618494
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
13. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
14. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.
Tchernev G; Orfanos CE
J Cutan Pathol; 2007 Mar; 34(3):247-56. PubMed ID: 17302609
[TBL] [Abstract][Full Text] [Related]
16. P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas.
Conscience I; Jovenin N; Coissard C; Lorenzato M; Durlach A; Grange F; Birembaut P; Clavel C; Bernard P
Eur J Dermatol; 2006; 16(5):518-22. PubMed ID: 17101472
[TBL] [Abstract][Full Text] [Related]
17. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.
Zhuang L; Scolyer RA; Lee CS; McCarthy SW; Cooper WA; Zhang XD; Thompson JF; Hersey P
Histopathology; 2009 Mar; 54(4):462-70. PubMed ID: 19309398
[TBL] [Abstract][Full Text] [Related]
18. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma.
Ferrari D; Lombardi M; Ricci R; Michiara M; Santini M; De Panfilis G
J Cutan Pathol; 2007 Sep; 34(9):705-12. PubMed ID: 17696918
[TBL] [Abstract][Full Text] [Related]
19. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
[TBL] [Abstract][Full Text] [Related]
20. Idiosyncrasies of scalp melanoma.
Rigual NR; Cheney RT; Iwenofu OH; Li Q; Loree TR; Popat SR; Merzianu M
Laryngoscope; 2007 Aug; 117(8):1354-8. PubMed ID: 17592396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
